Sung H, Ferlay J, Siegel RL, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71(3):209–49.

Article  PubMed  Google Scholar 

Iihara H, Ishihara M, Matsuura K, Kurahashi S, Takahashi T, Kawaguchi Y, et al. Pharmacists contribute to the improved efficiency of medical practices in the outpatient cancer chemotherapy clinic. J Eval Clin Pract. 2012;18:753–60.

Article  PubMed  Google Scholar 

Adam R, Kitano Y. Multidisciplinary approach of liver metastases from colorectal cancer. Ann Gastroenterol Surg. 2019;3:50–6.

Article  PubMed  PubMed Central  Google Scholar 

Yamada Y, Fujii H, Watanabe D, Kato-Hayashi H, Ohata K, Kobayashi R et al. Severe Neutropenia is Associated with Better Clinical outcomes in patients with Advanced Pancreatic Cancer who receive modified FOLFIRINOX therapy. Cancers (Basel). 2018;10.

Fujii H, Matsuhashi N, Kitahora M, Takahashi T, Hirose C, Iihara H, et al. Bevacizumab in combination with TAS-102 improves clinical outcomes in patients with refractory metastatic colorectal cancer: a retrospective study. Oncologist. 2020;25:e469–76.

Article  CAS  PubMed  Google Scholar 

Watanabe D, Fujii H, Yamada Y, Matsuhashi N, Makiyama A, Iihara H, et al. Association of albumin-bilirubin score in patients with colorectal cancer receiving later-line chemotherapy with regorafenib. Int J Clin Oncol. 2021;26:1257–63.

Article  CAS  PubMed  Google Scholar 

Hirose C, Fujii H, Iihara H, Ishihara M, Nawa-Nishigaki M, Kato-Hayashi H, et al. Real-world data of the association between quality of life using the EuroQol 5 dimension 5 level utility value and adverse events for outpatient cancer chemotherapy. Support Care Cancer. 2020;28:5943–52.

Article  PubMed  PubMed Central  Google Scholar 

Fujii H, Koda M, Sadaka S, Ohata K, Kato-Hayashi H, Iihara H, et al. Anorexia, pain and peripheral neuropathy are associated with a decrease in quality of life in patients with advanced pancreatic cancer receiving outpatient chemotherapy — a retrospective observational study. J Pharm Health Care Sci. 2021;7:27.

Article  PubMed  PubMed Central  Google Scholar 

Fujii H, Ueda Y, Hirose C, Ohata K, Sekiya K, Kitahora M, et al. Pharmaceutical intervention for adverse events improves quality of life in patients with cancer undergoing outpatient chemotherapy. J Pharm Health Care Sci. 2022;8:8.

Article  PubMed  PubMed Central  Google Scholar 

Fujii H, Yamada Y, Watanabe D, Matsuhashi N, Takahashi T, Yoshida K, et al. Dose adjustment of irinotecan based on UGT1A1 polymorphisms in patients with colorectal cancer. Cancer Chemother Pharmacol. 2019;83:123–9.

Article  CAS  PubMed  Google Scholar 

Watanabe D, Fujii H, Matsuhashi N, Iihara H, Yamada Y, Ishihara T, et al. Dose Adjustment of Oxaliplatin based on renal function in patients with metastatic colorectal Cancer. Anticancer Res. 2020;40:2379–86.

Article  CAS  PubMed  Google Scholar 

Guyatt GH. Evidence-based medicine. ACP J Club. 1991;114(suppl 2):A–16.

Google Scholar 

Sackett DL, Rosenberg WM, Gray JA, Haynes RB, Richardson WS. Evidence based medicine: what it is and what it isn’t. BMJ. 1996;312(7023):71–2.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Buchan H. Gaps between best evidence and practice: causes for concern. Med J Aust. 2004;180(6 suppl):48–9.

Google Scholar 

Fujii H, Iihara H, Ishihara M, Takahashi T, Yoshida K, Itoh Y. Improvement of adherence to guidelines for antiemetic medication enhances emetic control in patients with colorectal cancer receiving chemotherapy of moderate emetic risk. Anticancer Res. 2013;33:5549–56.

CAS  PubMed  Google Scholar 

Bloechl-Daum B, Deuson RR, Mavros P, Hansen M, Herrstedt J. Delayed nausea and vomiting continue to reduce patients’ quality of life after highly and moderately emetogenic chemotherapy despite antiemetic treatment. J Clin Oncol. 2006;24:4472–8.

Article  CAS  PubMed  Google Scholar 

Hesketh PJ, Kris MG, Basch E, Bohlke K, Barbour SY, Clark-Snow RA, et al. Antiemetics: ASCO Guideline Update. J Clin Oncol. 2020;38:2782–97.

Article  CAS  PubMed  Google Scholar 

Jordan K, Chan A, Gralla RJ, Jahn F, Rapoport B, Ruhlmann CH, et al. Emetic risk classification and evaluation of the emetogenicity of antineoplastic agents-updated MASCC/ESMO consensus recommendation. Support Care Cancer. 2023;32:53.

Article  PubMed  PubMed Central  Google Scholar 

NCCN clinical practice guidelines in oncology: antiemesis, version 1. 2023. https://www.nccn.org/professionals/physician_gls/pdf/antiemesis.pdf. Accessed 23 Feb 2023.

Aogi K, Takeuchi H, Saeki T, Aiba K, Tamura K, Iino K, et al. Optimizing antiemetic treatment for chemotherapy-induced nausea and vomiting in Japan: Update summary of the 2015 Japan Society of Clinical Oncology Clinical Practice Guidelines for Antiemesis. Int J Clin Oncol. 2021;26:1–17.

Article  PubMed  Google Scholar 

Hori K, Kobayashi N, Atsumi H, Nagayama A, Kondoh M, Noge I, et al. Changes in compliance with Japanese antiemetic guideline for chemotherapy-induced nausea and vomiting: a nationwide survey using a distributed research network. Support Care Cancer. 2014;22:969–77.

Article  PubMed  Google Scholar 

Gilmore JW, Peacock NW, Gu A, Szabo S, Rammage M, Sharpe J, et al. Antiemetic guideline consistency and incidence of chemotherapy-induced nausea and vomiting in US community oncology practice: INSPIRE study. J Oncol Pract. 2014;10:68–74.

Article  PubMed  Google Scholar 

Aapro M, Molassiotis A, Dicato M, Peláez I, Rodríguez-Lescure Á, Pastorelli D, et al. The effect of guideline-consistent antiemetic therapy on chemotherapy-induced nausea and vomiting (CINV): the Pan European Emesis Registry (PEER). Ann Oncol. 2012;23:1986–92.

Article  CAS  PubMed  Google Scholar 

Chan A, Low XH, Yap KY. Assessment of the relationship between adherence with antiemetic drug therapy and control of nausea and vomiting in breast cancer patients receiving anthracycline-based chemotherapy. J Manag Care Pharm. 2012;18:385–94.

PubMed  Google Scholar 

Yamada M, Iihara H, Fujii H, Ishihara M, Matsuhashi N, Takahashi T, et al. Prophylactic effect of oral minocycline in combination with topical steroid and skin care against Panitumumab-induced Acneiform Rash in Metastatic Colorectal Cancer patients. Anticancer Res. 2015;35:6175–81.

CAS  PubMed  Google Scholar 

Van Cutsem E, Peeters M, Siena S, Humblet Y, Hendlisz A, Neyns B, et al. Open-label phase III trial of panitumumab plus best supportive care compared with best supportive care alone in patients with chemotherapy-refractory metastatic colorectal cancer. J Clin Oncol. 2007;25:1658–64.

Article  PubMed  Google Scholar 

Boone SL, Rademaker A, Liu D, Pfeiffer C, Mauro DJ, Lacouture ME. Impact and management of skin toxicity associated with anti-epidermal growth factor receptor therapy: survey results. Oncology. 2007;72:152–9.

Article  CAS  PubMed  Google Scholar 

Orditura M, De Vita F, Galizia G, Lieto E, Vecchione L, Vitiello F, et al. Correlation between efficacy and skin rash occurrence following treatment with the epidermal growth factor receptor inhibitor cetuximab: a single institution retrospective analysis. Oncol Rep. 2009;21:1023–8.

Article  CAS  PubMed  Google Scholar 

Lacouture ME, Mitchell EP, Piperdi B, Pillai MV, Shearer H, Iannotti N, et al. Skin toxicity evaluation protocol with panitumumab (STEPP), a phase II, open-label, randomized trial evaluating the impact of a pre-emptive skin treatment regimen on skin toxicities and quality of life in patients with metastatic colorectal cancer. J Clin Oncol. 2010;28:1351–7.

Article  CAS  PubMed  Google Scholar 

Fujii H, Iihara H, Suzuki A, Kobayashi R, Matsuhashi N, Takahashi T, et al. Hypomagnesemia is a reliable predictor for efficacy of anti-EGFR monoclonal antibody used in combination with first-line chemotherapy for metastatic colorectal cancer. Cancer Chemother Pharmacol. 2016;77:1209–15.

Article  CAS  PubMed  Google Scholar 

Van Cutsem E, Köhne CH, Hitre E, Zaluski J, Chang Chien CR, Makhson A, et al. Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer. N Engl J Med. 2009;360:1408–17.

Article  PubMed  Google Scholar 

Douillard JY, Siena S, Cassidy J, Tabernero J, Burkes R, Barugel M, et al. Randomized, phase III trial of panitumumab with infusional fluorouracil, leucovorin, and oxaliplatin (FOLFOX4) versus FOLFOX4 alone as first-line treatment in patients with previously untreated metastatic colorectal cancer: the PRIME study. J Clin Oncol. 2010;28:4697–705.

Article  CAS  PubMed  Google Scholar 

Groenestege WM, Thébault S, van der Wijst J, van den Berg D, Janssen R, Tejpar S, et al. Impaired basolateral sorting of pro-EGF causes isolated recessive renal hypomagnesemia. J Clin Invest. 2007;117:2260–7.

Article  CAS  PubMed  PubMed C